<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="195"><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9859"></Trial><Drug id="10593">Meningitec</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9859"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="79465"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11526"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9949"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1128</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15333"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="17509"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11963"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>330</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="172270"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>869</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="161697"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1560</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="17279"></Trial><Drug id="41069">second-generation MMR vaccine, Berna</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>467</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10223"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="91153"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="203343"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10223"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="307614"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>600</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="79465"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="340960"></Trial><Drug id="59852">Pentaxim</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="268409"></Trial><Drug id="75100">MV-CHIK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>263</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="233238"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="206205"></Trial><Drug id="99042">double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="233238"></Trial><Drug id="12813">Rotarix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="269874"></Trial><Drug id="60890">SA-14-14-2</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>628</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="203343"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="172270"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>869</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60653"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>822</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15243"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1390</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15250"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85664"></Trial><Drug id="56585">Vaxelis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="79465"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="77052"></Trial><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11387"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>559</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60684"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1551</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85664"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="94105"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="104131"></Trial><Drug id="83793">Trivivac</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15317"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="79465"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15335"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="203343"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="340960"></Trial><Drug id="22877">RotaTeq</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="44865"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="233238"></Trial><Drug id="17674">Infanrix Quinta</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="307614"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>600</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A phase III clinical trial of JVC-001 for the prevention of measles, mumps and rubella infection</ProtocolTitle><TrialStatus>Planned</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="350532"></Trial><Drug id="99518">JVC-001</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="377732"></Trial><Drug id="115970">live-attenuated viral vaccine (sc, measles/rubella virus infection), Indian Immunologicals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>55</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60653"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>822</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="94105"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11418"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>5803</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9949"></Trial><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1128</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="102759"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>458</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11388"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>970</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Measles, Mumps, and Rubella (MMR) Immunity in College Students</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="59758"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>74</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11388"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>970</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="124248"></Trial><Drug id="56585">Vaxelis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single- Dose and Multidose Presentations</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="106360"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>240</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="88475"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15250"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9965"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1378</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9967"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1664</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="94105"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="187831"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of the immunogenicity and safety of Japanese encephalitis vaccine when given with measles-mumps-rubella vaccine</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="268796"></Trial><Drug id="60890">SA-14-14-2</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>628</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10223"></Trial><Drug id="39031">Menveo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85664"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="124248"></Trial><Drug id="55366">Nimenrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="91153"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Comparative Study of Immunogenicity and Safety of a two-dose Regimen of ProQuad Manufactured With rHA</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11632"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1620</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="88475"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="79465"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15301"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>799</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="94105"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11515"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60050"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11526"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15301"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>799</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="187831"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="17279"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>467</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Study To Compare The Immune Response And Safety Of Measles Vaccine Manufactured By Cadila Healthcare Ltd, With Measles Vaccine Manufactured By Serum Institute Of India Ltd, In Children 9 to 12 Months Of Age</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="229988"></Trial><Drug id="97346">measles vaccine, Cadila Healthcare</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>327</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11425"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Long-term Follow-up of Measles Antibodies</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="14946"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1960</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="265194"></Trial><Drug id="47199">Adacel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>MMR at 6 Months Trial</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="364134"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>6500</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A clinical trial to assess the safety and protective efficacy of Biological Es Measles-Rubella Vaccine in 9 to 12 months old Infants in India</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="266205"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>600</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and safety of GSK Biologicals malaria vaccine given at 6,7.5 and 9 months of age coadministered with measles,rubella and yellow fever vaccines</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="261663"></Trial><Drug id="14289">malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>700</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A Phase I Study of MVA-BN Vector Vaccine to Evaluate Safety and Immunogenicity in Healthy Volunteers</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9026"></Trial><Drug id="54328">MVA-mBN85B</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10599"></Trial><Drug id="17821">Infanrix HeXa</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>955</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>ProQuad Intramuscular versus Subcutaneous</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11634"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>405</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9965"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1378</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="184151"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1412</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Safety Study of ProQuad rHA in Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11426"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3388</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Safety Study of a Refrigerator-Stable Formulation of Varivax</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11524"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>507</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="88475"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60653"></Trial><Drug id="10530">Comvax</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>822</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15301"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>799</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GSK Biologicals 208136 Vaccine Formulated With New Measles and Rubella Working Seeds</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="54026"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>498</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study To Determine If Upper Respiratory Tract Infection (URI) Affects The Seroconversion Rate Or Quantitative Response To Each Component Of ProQuad</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15334"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>149</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11418"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>5803</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60050"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15243"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1390</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15250"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="124248"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="102759"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>458</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="102759"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>458</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="184151"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1412</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11526"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Efficacy of ProQuad in Children 6 to 24 Months Being Evaluated for Solid Organ Transplant</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="254035"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="198691"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>8309</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10223"></Trial><Drug id="84867">Vaxem HIB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="233238"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11423"></Trial><Drug id="14438">Avaxim</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>470</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="273428"></Trial><Drug id="101326">MV-NIS (lung cancer), Vyriad</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>4</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="273428"></Trial><Drug id="72699">atezolizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>4</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="298150"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>432</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="265194"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>To Assess the Safety and Tolerability of Measles, Mumps, Rubella and Varicella Vaccine (Live-Attenuated, Freeze-Dried) in Healthy Adult Male Human Subjects</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="243853"></Trial><Drug id="97994">MMRV vaccine, Zydus Cadila Healthcare</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="124248"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10810"></Trial><Drug id="7080">Pneumovax 23</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11515"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="77052"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="187831"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15243"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1390</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9859"></Trial><Drug id="55366">Nimenrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11389"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1439</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="124248"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11525"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>752</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="91153"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="94105"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9949"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1128</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11388"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>970</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="77052"></Trial><Drug id="30214">diphtheria/tetanus/pertussis vaccine, sanofi pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="340960"></Trial><Drug id="39031">Menveo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="44865"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry>Japanese Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Non-blind, randomized trial to evaluate the safety and immunogenicity of JVC-001 intended for Japanese healthy children</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="244020"></Trial><Drug id="99518">JVC-001</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Third MMR Vaccine Dose In Young Adults</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="270107"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="340960"></Trial><Drug id="102979">quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="269874"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>628</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10810"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11511"></Trial><Drug id="3263">Vaqta</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1800</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="77052"></Trial><Drug id="49241">Quadracel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="59936"></Trial><Drug id="54328">MVA-mBN85B</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>90</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60684"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1551</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10599"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>955</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11525"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>752</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11526"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="91153"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85664"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry>African Ancestry</Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Phase III Study Of Prophylactic Antibiotics in Measles</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11380"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>218</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15317"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15335"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85664"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11418"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>5803</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="17509"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="124248"></Trial><Drug id="22877">RotaTeq</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="132011"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="203343"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="132011"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="17509"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="200688"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4050</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="44865"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="233238"></Trial><Drug id="42065">Bexsero</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A Post Licensure Clinical Trial to Assess the Safety and Tolerability of BE’s Measles-rubella Vaccine in 9 to 12 Months Old Healthy Infants in a Single-Dose</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="378426"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="268409"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>263</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (phase III)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="357452"></Trial><Drug id="113162">MRVAC</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>756</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="60050"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9965"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1378</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11515"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11511"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1800</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="77052"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative Study To Evaluate The Efficacy Of Priorix With ROR Vax</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15245"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>4000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>Study to evaluate frozen versus refrigerated MMRV (combined Measles, Mumps, Rubella, and Varicella) investigational vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="12456"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1200</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="83852"></Trial><Drug id="10593">Meningitec</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>716</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9967"></Trial><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1664</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="203343"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="88475"></Trial><Drug id="57017">Kinrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="9967"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>1664</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85664"></Trial><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15317"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15333"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15335"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="85837"></Trial><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="11384"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>110</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="132011"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients></Row><Row><Ancestry>Asian Ancestry</Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A Phase IV, Open, Multicentric, Post-marketing Surveillance Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals’ Live Attenuated Measles-Mumps-Rubella vaccine (Priorix) in Korean Subjects Administered According to the Prescribing Information</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="172850"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>732</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Immunological Effect of Early Extra MMR Immunization in Infants Between 6 and 12 Months of Age in an Outbreak Setting</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="156178"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Comparative Study To Evaluate The Efficacy Of Priorix With ROR Vax</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15245"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>4000</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="83852"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>716</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="15333"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="218981"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>14</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="10223"></Trial><Drug id="15298">Pentacel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="161697"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>1560</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="91153"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety</Endpoint><ProtocolTitle>A phase-I study to evaluate the safety and tolerability of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children in a single-dose schedule</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="246741"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="298801"></Trial><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>873</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><Trial id="233238"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>